Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 179

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 179
---
ix Months EndedJune 30,2025202420252024Weighted average number of stock options6,858 7,311 6,921 7,486 2025 Notes2,821 — 2,821 — Weighted average number of RSUs4,703 1,304 4,417 1,267 Weighted average ESPP share options101 — 102 26       Total14,483 8,615 14,261 8,779 

NOTE 14—INCOME TAXES 

(Loss) income before income taxes and income tax expense are as follows (dollar amounts in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(Loss) income before income taxes:   Domestic$(4,214)$36,996 $6,459 $50,653    Foreign2,287 (412)320 (429)Total (loss) income before income taxes$(1,927)$36,584 $6,779 $50,224 Income tax expense$2,920 $17,698 $6,814 $22,359 Effective tax rate(152)%48 %101 %45 %

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 30

The Company’s income tax expense represents the estimated annual effective tax rate applied to the year-to-date operating results, adjusted for certain discrete tax items.The Company’s effective tax rate for the three and six months ended June 30, 2025 was primarily impacted by costs related to non-deductible stock-based compensation, non-deductible executive compensation and a non-U.S. valuation allowance.The Company’s effective tax rate for the three and six months ended June 30, 2024 include costs related to non-deductible stock-based compensation, primarily related to expired stock options, and non-deductible executive compensation, partially offset by tax creditsAs of both June 30, 2025 and December 31, 2024, the Company had an income tax payable balance of $5.1 million that was included in other liabilities within the condensed consolidated balance sheet. As of June 30, 2025 and December 31, 2024, the Company had $0.9 million and $0.7 million, respectively, of current